Samar Sheth, MD
Cardiovascular Disease · Houston, TXNPI 1013146901
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 92.4% of the total across 760 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 58 manufacturers, the largest accounting for just 15.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $6,559 and has fallen 60.4% since, to $2,595 in 2025.
Across 760 payments — averaging $33.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abiomed$4K
- Abbott$4K
- Medtronic$3K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$2K
- Boston Scientific$1K
- Novartis$961
- plus $11K from 52 others
Across 13 payments — averaging $17,179 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$147K
- Siemens Medical Solutions USA, Inc.$76K
- Abiomed$224
What the payments were for
- Travel & lodging$1,9248%
- Food & beverage$23,63192%
- Education$320%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Impella$3,319
- CoreValve Evolut$1,335
- Mitra Clip system$933
- Alto Abdominal Stent Graft System$584
- FARXIGA$351
- Accent Pacemaker$318
- OPTIMIZER SMART SYSTEM$306
- VenaSeal$290
- GENERAL - THERAPIES$282
- XIENCE SKYPOINT$273
- COREVALVE EVOLUT R$260
- EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX$159
- ATRICLIP LAA EXCLUSION SYSTEM$159
- SYNERGY ABLATION SYSTEM$159
- ATRICURE CRYOICE CRYOSPHERE CRYOABLATION SYSTEM$159
- ISOLATOR SURGICAL ABLATION SYSTEM$159
- OMNILINK ELITE$159
- Indigo$148
- ELUVIA$145
- Diamondback Coronary$143
How this compares
$25,588 in reported general payments places this provider in the 85th percentile of 1,515 cardiovascular disease providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 229 | $268,313 |
| EntrestoSacubitril/Valsartan | 91 | $129,544 |
| XareltoRivaroxaban | 83 | $113,017 |
| Repatha SureclickEvolocumab | 82 | $87,668 |
| JardianceEmpagliflozin | 95 | $86,155 |
| FarxigaDapagliflozin Propanediol | 54 | $56,641 |
| OzempicSemaglutide | 47 | $56,556 |
| MounjaroTirzepatide | 24 | $28,547 |
| NexlizetBempedoic Acid/Ezetimibe | 16 | $16,628 |
| MultaqDronedarone Hcl | 14 | $10,151 |
| NexletolBempedoic Acid | 11 | $6,785 |
| Metoprolol Succinate | 326 | $5,808 |
| Atorvastatin Calcium | 307 | $3,600 |
| ClopidogrelClopidogrel Bisulfate | 188 | $2,915 |
| Rosuvastatin Calcium | 213 | $2,892 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $587 | $268,313229 claims |
| NovartisEntresto | $961 | $129,54491 claims |
| Johnson & JohnsonXarelto | $905 | $113,01783 claims |
| Boehringer IngelheimJardiance | $366 | $86,15595 claims |
| AstraZenecaFarxiga | $790 | $56,64154 claims |
| Novo NordiskOzempic | $508 | $56,55647 claims |
| Lilly USA, LLCMounjaro | $18 | $28,54724 claims |
| Esperion Therapeutics, Inc.Nexlizet, Nexletol | $353 | $23,41327 claims |
| Sanofi-aventis U.S. LLCMultaq | $49 | $10,15114 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,515 cardiovascular disease providers in Texas.
Other cardiovascular disease in Houston
- Biykem BozkurtHouston$606K
- Reynolds DelgadoHouston$471K
- Christie BallantyneHouston$413K
- Asif AliHouston$411K
- Sanjay ManiarHouston$263K
- Joggy GeorgeHouston$231K
- Jerry EstepHouston$226K
- Stephen LittleHouston$144K
- Akira NishikawaHouston$109K
- Andres MesaHouston$103K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.